Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias

Sofie A Gevaert¹, Sigrun Halvorsen², Peter R Sinnaeve³, Antonia Sambola⁴, Geeta Gulati², Patrizio Lancellotti⁵, Peter Van Der Meer⁶, Alexander R Lyon⁷, Dimitrios Farmakis⁸, Geraldine Lee⁹, Giuseppe Boriani¹⁰, Ashutosh Wechalekar¹¹, Alicia Okines¹², Riccardo Asteggiano^{13

14}, Alain Combes^{15

16}, Roman Pfister¹⁷, Jutta Bergler-Klein¹⁸, Maddalena Lettino¹⁹

Affiliations

¹ Department of Cardiology, Ghent University Hospital, Gent, Belgium.
² Department of Cardiology, Oslo University Hospital Ulleval, and University of Oslo, Oslo, Norway.
³ Department of Cardiology, University Hospital Leuven, Leuven, Belgium.
⁴ Department of Cardiology, University Hospital Vall d'Hebron, Universitat Autonòma, CIBER-CV, Barcelona, Spain.
⁵ University of Liège Hospital, GIGA Cardiovascular Science, Department of Cardiology, CHU Sart Tilman, Liège, Belgium.
⁶ Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
⁷ Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College London, London, UK.
⁸ University of Cyprus Medical School, Nicosia, Cyprus.
⁹ Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College, London, UK.
¹⁰ Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico Di Modena, Modena, Italy.
¹¹ Department of Haematology, University College London/University College London Hospitals, London, UK.
¹² Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
¹³ Insubria University, Varese, Italy.
¹⁴ LARC (Laboratorio Analisi e Ricerca Clinica), Turin, Italy.
¹⁵ Medical-Surgical ICU, Hôpital Pitié-Salpêtrière, Paris, France.
¹⁶ Sorbonne University, Institute of Cardiometabolism and Nutrition, Paris, France.
¹⁷ Department III of Internal Medicine, Heart Center, University of Cologne, Cologne, Germany.
¹⁸ Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
¹⁹ Department of Cardiology, San Gerardo Hospital, ASST-Monza, Monza, Italy.

PMID: 36226746
DOI: 10.1093/ehjacc/zuac107

Free article

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias

Sofie A Gevaert et al. Eur Heart J Acute Cardiovasc Care. 2022.

Free article

. 2022 Nov 30;11(11):865-874.

doi: 10.1093/ehjacc/zuac107.

Authors

Affiliations

¹ Department of Cardiology, Ghent University Hospital, Gent, Belgium.
² Department of Cardiology, Oslo University Hospital Ulleval, and University of Oslo, Oslo, Norway.
³ Department of Cardiology, University Hospital Leuven, Leuven, Belgium.
⁴ Department of Cardiology, University Hospital Vall d'Hebron, Universitat Autonòma, CIBER-CV, Barcelona, Spain.
⁵ University of Liège Hospital, GIGA Cardiovascular Science, Department of Cardiology, CHU Sart Tilman, Liège, Belgium.
⁶ Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
⁷ Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College London, London, UK.
⁸ University of Cyprus Medical School, Nicosia, Cyprus.
⁹ Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College, London, UK.
¹⁰ Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico Di Modena, Modena, Italy.
¹¹ Department of Haematology, University College London/University College London Hospitals, London, UK.
¹² Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
¹³ Insubria University, Varese, Italy.
¹⁴ LARC (Laboratorio Analisi e Ricerca Clinica), Turin, Italy.
¹⁵ Medical-Surgical ICU, Hôpital Pitié-Salpêtrière, Paris, France.
¹⁶ Sorbonne University, Institute of Cardiometabolism and Nutrition, Paris, France.
¹⁷ Department III of Internal Medicine, Heart Center, University of Cologne, Cologne, Germany.
¹⁸ Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
¹⁹ Department of Cardiology, San Gerardo Hospital, ASST-Monza, Monza, Italy.

PMID: 36226746
DOI: 10.1093/ehjacc/zuac107

Abstract

Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to cancer itself or cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. The management of acute coronary syndromes and acute pericardial diseases in cancer patients was covered in part 1 of a clinical consensus document. This second part focusses on acute heart failure, acute myocardial diseases, venous thromboembolic diseases and acute arrhythmias.

Keywords: Acute heart failure; Acute toxicity; Arrhythmia; Cancer; Cardiac implanted electronic devices (CIED); Cardiotoxicity; Myocarditis; Pulmonary embolism; Takotsubo syndrome; Venous thromboembolic disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P.L.: nothing in relation to this work. A.S.: nothing in relation to this work. G.G.: has received speaker honoraria from Novartis, Orion Pharma, AstraZeneca, and Bristol-Myers Squibb. R.A.: nothing in relation to this work. G.B.: nothing in relation to this work. S.H.: nothing in relation to this work. G.L.: nothing in relation to this work. D.F.: speaker’s honoraria or advisory board fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo Pharmaceuticals, Menarini, Novartis, Orion Pharma, Roche Diagnostics. S.G.: speaker’s and advisory fees (all institutional) from AstraZeneca, Daiichi-Sankyo, Boehringer. P.S.: speaker’s and advisory fees (all institutional) from AstraZeneca, Daiichi-Sankyo, Bayer, Boehringer, Pfizer, BMS, Amgen, Sanofi. P.V.D.M.: consultancy and/or Servier, Novartis, Pfizer, Pharmacosmos, Ionis. Supported by the ERC (StG 715732). A.R.L.: speaker, advisory board, or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens-Cilag Ltd., Clinigen, Eli Lily, Eisai, Bristol-Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA, and Heartfelt Technologies Ltd. A.O.: speaker’s and advisory fees from Seagen, Roche, Diaichi-Sankyo, and Astra Zeneca. Travel support from Lilly, Astra Zeneca, and Leo Pharmaceuticals. A.W.: honorarium, advisory board or consultancy fees: Janssen Cilag, GSK, Alexion, Caelum, Takeda, Celgene.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

Fondation Leducq Network of Excellence

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical